Comparative Pharmacology
Head-to-head clinical analysis: ULTACAN versus ULTACAN FORTE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ULTACAN versus ULTACAN FORTE.
ULTACAN vs ULTACAN FORTE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Histamine H2-receptor antagonist; inhibits gastric acid secretion by competitively blocking H2 receptors on parietal cells.
Cimetidine is a histamine H2-receptor antagonist that inhibits gastric acid secretion by competitively blocking histamine at H2 receptors on parietal cells.
1-2 mg/kg intravenously every 4-6 hours as needed for moderate to severe pain. Maximum single dose: 10 mg.
1 tablet (5 mg bisoprolol) orally once daily; maximum 10 mg once daily.
None Documented
None Documented
Terminal elimination half-life is 3-5 hours in adults with normal renal function; prolonged to 12-20 hours in severe renal impairment (CrCl < 30 mL/min).
Terminal elimination half-life: 3–5 hours (prolonged to 12–24 hours in severe renal impairment; dose adjustment required if CrCl < 30 mL/min).
Renal excretion accounts for approximately 60-70% of the administered dose as unchanged drug, with biliary/fecal elimination contributing 20-30%.
Renal (90% as unchanged drug), biliary/fecal (10%)
Category C
Category C
Viscosupplement (Hyaluronic Acid)
Viscosupplement (Hyaluronic Acid)